Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 1-Year High at $52.25

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares changing hands. The stock had previously closed at $52.25.

Recordati Industria Chimica e Farmaceutica Stock Performance

The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The firm has a fifty day simple moving average of $52.03 and a two-hundred day simple moving average of $51.75. The firm has a market cap of $10.78 billion, a PE ratio of 18.80 and a beta of 0.33.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 EPS for the quarter. The company had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%. Equities analysts forecast that Recordati Industria Chimica e Farmaceutica S.p.A. will post 2.92 EPS for the current year.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.